Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles
Guardado en:
| Publicado en: | Frontiers in Pharmacology vol. 15 (Oct 2024), p. 1465055-1465083 |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , , |
| Publicado: |
Frontiers Media SA
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3279062144 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1663-9812 | ||
| 024 | 7 | |a 1465055 |2 doi | |
| 035 | |a 3279062144 | ||
| 045 | 2 | |b d20241001 |b d20241031 | |
| 100 | 1 | |a Sameh, Salma |u Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt | |
| 245 | 1 | |a Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles | |
| 260 | |b Frontiers Media SA |c Oct 2024 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a IntroductionCancer is the second most widespread cause of mortality following cardiovascular disorders, and it imposes a heavy global burden. Nowadays, herbal nutraceutical products with a plethora of bioactive metabolites represent a foundation stone for the development of promising chemopreventive and anticancer agents. Certain members of the family Malvaceae have traditionally been employed to relieve tumors. The literature concerning the chemopreventive and anticancer effects of the plant species along with the isolated cytotoxic phytometabolites was reviewed. Based on the findings, comprehensive computational modelling studies were performed to explore the pharmacokinetic and pharmacodynamic profiles of the reported cytotoxic metabolites to present basis for future plant-based anticancer drug discovery.MethodsAll the available information about the anticancer research in family Malvaceae and its cytotoxic phytometabolites were retrieved from official sources. Extensive search was carried out using the keywords Malvaceae, cancer, cytotoxicity, mechanism and signalling pathway. Pharmacokinetic study was performed on the cytotoxic metabolites using SWISS ADME model. Acute oral toxicity expressed as median lethal dose (LD50) was predicted using Pro Tox 3.0 web tool. The compounds were docked using AutoDock Vina platform against epidermal growth factor receptor (EGFR kinase enzyme) obtained from the Protein Data Bank. Molecular dynamic simulations and MMGBSA calculations were performed using GROMACS 2024.2 and gmx_MMPBSA tool v1.5.2.ResultsOne hundred forty-five articles were eligible in the study. Several tested compounds showed safe pharmacokinetic properties. Also, the molecular docking study showed that the bioactive metabolites possessed agreeable binding affinities to EGFR kinase enzyme. Tiliroside (25), boehmenan (30), boehmenan H (31), and isoquercetin (22) elicited the highest binding affinity toward the enzyme with a score of −10.4, −10.4, −10.2 and −10.1 Kcal/mol compared to the reference drug erlotinib having a binding score equal to −9 Kcal/mol. Additionally, compounds 25 and 31 elicited binding free energies equal to −42.17 and −42.68 Kcal/mol, respectively, comparable to erlotinib.DiscussionOverall, the current study presents helpful insights into the pharmacokinetic and pharmacodynamic properties of the reported cytotoxic metabolites belonging to family Malvaceae members. The molecular docking and dynamic simulations results intensify the roles of secondary metabolites from medicinal plants in fighting cancer. | |
| 653 | |a Cytotoxicity | ||
| 653 | |a Metastasis | ||
| 653 | |a Toxicity | ||
| 653 | |a Hydrogen bonds | ||
| 653 | |a Phytochemicals | ||
| 653 | |a Mutation | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Medicinal plants | ||
| 653 | |a Lethal dose | ||
| 653 | |a Drugs | ||
| 653 | |a Kinases | ||
| 653 | |a Cancer | ||
| 653 | |a Bioavailability | ||
| 653 | |a Proteins | ||
| 653 | |a Epidermal growth factor receptors | ||
| 653 | |a Herbal medicine | ||
| 653 | |a Pharmacodynamics | ||
| 653 | |a Pharmacokinetics | ||
| 653 | |a Cardiovascular diseases | ||
| 653 | |a Secondary metabolites | ||
| 653 | |a Antineoplastic drugs | ||
| 653 | |a Metabolites | ||
| 653 | |a Side effects | ||
| 653 | |a Bioactive compounds | ||
| 653 | |a Ligands | ||
| 653 | |a Carcinogens | ||
| 653 | |a Cell growth | ||
| 653 | |a Signal transduction | ||
| 653 | |a Malvaceae | ||
| 700 | 1 | |a Elissawy, Ahmed M |u Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt, Center of Drug Discovery Research and Development, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt | |
| 700 | 1 | |a Al-Sayed, Eman |u Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt | |
| 700 | 1 | |a Labib, Rola M |u Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt | |
| 700 | 1 | |a Hsueh-Wei, Chang |u Department of Biomedical Science and Environmental Biology, and PhD Program in Life Sciences, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan | |
| 700 | 1 | |a Szu-Yin, Yu |u School of Pharmacy and Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan | |
| 700 | 1 | |a Fang-Rong, Chang |u School of Pharmacy and Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan | |
| 700 | 1 | |a Yang, Shyh-Chyun |u School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan | |
| 700 | 1 | |a Abdel Nasser B. Singab |u Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt, Center of Drug Discovery Research and Development, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt | |
| 773 | 0 | |t Frontiers in Pharmacology |g vol. 15 (Oct 2024), p. 1465055-1465083 | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3279062144/abstract/embedded/H09TXR3UUZB2ISDL?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3279062144/fulltext/embedded/H09TXR3UUZB2ISDL?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3279062144/fulltextPDF/embedded/H09TXR3UUZB2ISDL?source=fedsrch |